Shorts

$Following the FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for patients with relapsed/refractory multiple myeloma, Surbhi Sidana, MD, discussed what clinicians should expect when it comes to administering the novel CELMoD.$

CELMoD Approval Brings “Familiar” Dosing Protocols to Multiple Myeloma

8 days ago

by

Surbhi Sidana, MD

Nevine Hanna, MD, MPH, FACRO, DABR, expressed that true AI-driven progress in cancer care hinges on seamlessly integrating disjointed data streams while maintaining rigorous privacy standards.

How Can Solving Data Fragmentation Help Unlock AI's Potential in Oncology?

9 days ago

by

Nevine Hanna, MD, MPH, FACRO, DABR

According to Nicholas Hornstein, MD, PhD, daraxonrasib is now an option for patients who are simply not “up” for systemic chemotherapy.

Daraxonrasib’s Approval is for All Comers with Pancreatic Cancer

10 days ago

by

Nicholas James Hornstein, MD, PhD

Nevine Hanna, MD, MPH, FACRO, DABR, emphasized that AI in oncology isn't replacing clinical judgment but eliminating systemic friction to give physicians time back with their patients.

How Can AI Preserve the Human Connection in Cancer Care?

11 days ago

by

Nevine Hanna, MD, MPH, FACRO, DABR

Speaking with CancerNetwork®, Barbara Burtness, MD, highlighted how subcutaneous administration could simplify delivery, while noting that managing associated adverse effects will remain vital across care settings.

Streamlining Subcutaneous Amivantamab Administration in HNSCC Workflows

19 days ago

by

Barbara Burtness, MD

In a conversation with CancerNetwork®, Barbara Burtness, MD, explained how co-targeting EGFR and MET addresses key pathways involved in epithelial-to-mesenchymal transition (EMT) and treatment resistance.

Targeting EGFR and MET Resistance Pathways in HPV-Independent HNSCC

20 days ago

by

Barbara Burtness, MD

Multidisciplinary Care Key to Success in Robotic Whipple Pancreatic Surgery

Multidisciplinary Care Key to Success in Robotic Whipple Pancreatic Surgery

21 days ago

by

Mohamed Adam, MD

Yu-Wei Chen, MD, MS, of the University of California San Diego, highlighted promising therapeutic avenues from the 2026 Kidney Cancer Research Summit poised to shape the treatment landscape.

Emerging RCC Therapies: Casdatifan & PD-1/VEGF Bispecifics Signal Progress

25 days ago

by

Yu-Wei Chen, MD, MS

Yu-Wei Chen, MD, MS, shared insights on balancing efficacy and safety when considering novel combinations in the evolving adjuvant immunotherapy landscape for localized RCC.

Navigating Adjuvant Immunotherapy Selection in Localized RCC

a month ago

by

Yu-Wei Chen, MD, MS

Edward S. Kim, MD, MBA, highlighted City of Hope's “just-in-time” trial activation protocol, which can open a specific clinical trial at a regional or community site in approximately 10 business days when a patient presents with a rare mutation.

How Can Health Networks Bring Clinical Trials Directly to Patients?

a month ago

by

Edward S. Kim, MD, MBA

Edward S. Kim, MD, MBA, highlights City of Hope’s commitment to ensuring every patient has the opportunity to participate in clinical trials.

How is City of Hope Expanding Access to Cancer Trials in Oncology?

a month ago

by

Edward S. Kim, MD, MBA

According to Goutham Vemana, MD, chair of the Department of Urology at Allegheny Health Network, proactive patient education and upfront symptom management are crucial for keeping patients on track with indwelling drug delivery devices.

Optimizing Treatment Tolerance During Intravesical Therapy for Bladder Cancer

a month ago

by

Goutham Vemana, MD

According to Goutham Vemana, MD, ongoing Bacillus Calmette-Guérin shortages across the US are driving patient anxiety and altering typical treatment sequences.

How Are BCG Shortages Reshaping Early-Stage Bladder Cancer Workflows?

a month ago

by

Goutham Vemana, MD

According to Mamta Parikh, MD, MS, patients who experience primary progressive disease within 6 months of starting this combination regimen often have highly aggressive, overt progression that serial ctDNA monitoring may not catch any earlier.

A “Controversial Take” on ctDNA Monitoring in Advanced Bladder Cancer

a month ago

by

Mamta Parikh, MD, MS

Mamta Parikh, MD, MS, cautioned that a current lack of robust prospective data makes interpreting and acting on results for ctDNA MRD monitoring challenging for clinicians.

More Data Needed To Validate ctDNA Monitoring in Bladder Cancer Care

a month ago

by

Mamta Parikh, MD, MS

In a conversation with CancerNetwork®, Adam D. Cohen, MD, spoke about the expanding role of CELMoDs as a novel therapeutic class in the treatment of patients with multiple myeloma.

CELMoDs Have “a Lot of Potential” in Multiple Myeloma Treatment Landscape

a month ago

by

Adam D. Cohen, MD

María Teresa Bourlon, MD, MS, FASCO, discussed why secondary overall survival trends cannot be definitively interpreted following the early closure of the phase 2 RADICAL/Alliance A031801 trial.

Interpreting Secondary End Points After Early Futility Closure in RCC

a month ago

by

María T. Bourlon, MD, MSc, FASCO

María Teresa Bourlon, MD, MS, FASCO, stressed that because pembrolizumab monotherapy already offers proven OS benefits, clinicians must weigh the higher potential toxicity of novel combination regimens against patient well-being.

Adjuvant RCC Standard of Care: OS and QOL Both Needed to Move the Needle

a month ago

by

María T. Bourlon, MD, MSc, FASCO

Could a Pill One Day Prevent KRAS-Driven Cancers Before They Start?

Could a Pill One Day Prevent KRAS-Driven Cancers Before They Start?

a month ago

by

Frank McCormick, PhD, FRS, DSc (Hon)

At the 2026 National ICE-T Conferences in Orlando, program director Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, spoke with CancerNetwork® about challenges surrounding payer coverage and reimbursement for CAR T-cell therapy and bispecific antibodies, detailing what she hopes payers could better understand about the treatment process.

Breaking Down Payer Misconceptions Surrounding Cellular Therapy

a month ago

by

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Why was KRAS Considered “Undruggable” for so Long?

Why was KRAS Considered “Undruggable” for so Long?

a month ago

by

Frank McCormick, PhD, FRS, DSc (Hon)

Herbert Lepor, MD, highlighted a critical issue in precision medicine: standard molecular tests often yield discordant results, and altering a treatment plan doesn’t automatically mean improving patient outcomes.

Are Prostate Cancer Molecular Signatures Driving the Right Decisions?

a month ago

by

Herbert Lepor, MD

When presented with validated long-term outcome data, most men with intermediate-risk prostate cancer favor a focal approach over radical intervention, according to Herbert Lepor, MD.

Seven-Year Data Drive Patient Preference for Focal Prostate Cancer Therapy

a month ago

by

Herbert Lepor, MD

At the 2026 National ICE-T Conference, program director Megan Melody, MD, MS, spoke with CancerNetwork® about how access to novel cellular therapies was a common theme across different sessions dedicated to multiple myeloma, leukemia, lymphoma, and other disease types.

Can CAR T-Cell Therapy Work in Community Oncology Settings?

2 months ago

Kirollos Hanna, PharmD, BCPS, BCOP, addressed optimal treatment strategies for patients with muscle invasive bladder cancer who experienced disease progression within 1 year of treatment with neoadjuvant pembrolizumab/enfortumab vedotin and cystectomy.

Where Does ctDNA Testing Fit Into the Recurrent MIBC Landscape?

2 months ago

by

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

In a conversation with CancerNetwork® at the 2026 National ICE-T Conference, Benjamin Diamond, MD, discussed the circumstances in which bispecific antibodies could best serve as a bridging therapy to CAR T-cell therapy or as definitive therapy alone among those with multiple myeloma.

Using Bispecific Antibodies as Definitive Therapy in Multiple Myeloma

2 months ago

by

Benjamin Diamond, MD

Kirollos Hanna, PharmD, BCPS, BCOP, broke down the correlation between ctDNA positivity and event-free survival in muscle-invasive bladder cancer.

Who Should Receive Adjuvant Immunotherapy After a Radical Cystectomy?

2 months ago

by

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

The Reality of Biopsy Needle Conservation Requests

The Reality of Biopsy Needle Conservation Requests

2 months ago

by

Harriet Borofsky, MD

How the Brevera Recall Triggered a Supply Chain Cascade

How the Brevera Recall Triggered a Supply Chain Cascade

2 months ago

by

Harriet Borofsky, MD

Sivraj Muralikrishnan, MD, highlighted findings from the RASolute 302 study evaluating daraxonrasib as a potential new benchmark for patients with RAS-mutated pancreatic cancer.

Practice-Changing Data in Metastatic PDAC: A New Second-Line Standard?

2 months ago

by

Sivraj Muralikrishnan, MD

Trending on CancerNetwork

Alcohol-Attributable Cancer Mortality Has Doubled in the US Since 1990

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

How Will Ropeginterferon Alfa’s Approval Impact Essential Thrombocythemia?

Unpacking Iberdomide’s FDA Approval and The Future of CELMoDs

Why Do Upsized Implants Show Lower Mastectomy Skin Flap Necrosis Rates?